版本:
中国

BRIEF-Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial

May 18 Revance Therapeutics Inc

* Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial

* Company also announced additional positive efficacy results and that RT002 was generally safe and well-tolerated

* In all three cohorts, RT002 injectable appeared to be generally safe and well-tolerated through week 24

* Revance Therapeutics- Based on phase 2 results, expects to discuss next steps in clinical program with US and EU regulatory agencies later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐